Logo image of PGNY

PROGYNY INC (PGNY) Stock Fundamental Analysis

NASDAQ:PGNY - US74340E1038 - Common Stock

22.64 USD
-0.5 (-2.16%)
Last: 8/26/2025, 8:00:01 PM
22.9 USD
+0.26 (+1.15%)
After Hours: 8/26/2025, 8:00:01 PM
Fundamental Rating

6

Overall PGNY gets a fundamental rating of 6 out of 10. We evaluated PGNY against 101 industry peers in the Health Care Providers & Services industry. PGNY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PGNY is not valued too expensively and it also shows a decent growth rate. These ratings would make PGNY suitable for quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

PGNY had positive earnings in the past year.
PGNY had a positive operating cash flow in the past year.
In the past 5 years PGNY has always been profitable.
In the past 5 years PGNY always reported a positive cash flow from operatings.
PGNY Yearly Net Income VS EBIT VS OCF VS FCFPGNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

PGNY's Return On Assets of 6.98% is amongst the best of the industry. PGNY outperforms 89.11% of its industry peers.
The Return On Equity of PGNY (10.31%) is better than 75.25% of its industry peers.
PGNY has a Return On Invested Capital of 10.87%. This is amongst the best in the industry. PGNY outperforms 82.18% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PGNY is in line with the industry average of 9.14%.
The last Return On Invested Capital (10.87%) for PGNY is above the 3 year average (8.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.98%
ROE 10.31%
ROIC 10.87%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
PGNY Yearly ROA, ROE, ROICPGNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

With a decent Profit Margin value of 4.28%, PGNY is doing good in the industry, outperforming 74.26% of the companies in the same industry.
PGNY's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 6.18%, PGNY is doing good in the industry, outperforming 64.36% of the companies in the same industry.
In the last couple of years the Operating Margin of PGNY has grown nicely.
Looking at the Gross Margin, with a value of 22.34%, PGNY is in line with its industry, outperforming 47.52% of the companies in the same industry.
PGNY's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.18%
PM (TTM) 4.28%
GM 22.34%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
PGNY Yearly Profit, Operating, Gross MarginsPGNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PGNY is creating some value.
The number of shares outstanding for PGNY has been reduced compared to 1 year ago.
Compared to 5 years ago, PGNY has more shares outstanding
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PGNY Yearly Shares OutstandingPGNY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PGNY Yearly Total Debt VS Total AssetsPGNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

PGNY has an Altman-Z score of 7.73. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
PGNY has a Altman-Z score of 7.73. This is amongst the best in the industry. PGNY outperforms 92.08% of its industry peers.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.73
ROIC/WACC1.22
WACC8.92%
PGNY Yearly LT Debt VS Equity VS FCFPGNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 2.70 indicates that PGNY has no problem at all paying its short term obligations.
PGNY has a better Current ratio (2.70) than 83.17% of its industry peers.
A Quick Ratio of 2.70 indicates that PGNY has no problem at all paying its short term obligations.
The Quick ratio of PGNY (2.70) is better than 83.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
PGNY Yearly Current Assets VS Current LiabilitesPGNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.35%.
Measured over the past years, PGNY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.77% on average per year.
PGNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.62%.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 38.42% on average per year.
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%

3.2 Future

PGNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.47% yearly.
PGNY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y7.88%
EPS Next 2Y33.27%
EPS Next 3Y29.43%
EPS Next 5Y32.47%
Revenue Next Year9.66%
Revenue Next 2Y9.74%
Revenue Next 3Y10.28%
Revenue Next 5Y8.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PGNY Yearly Revenue VS EstimatesPGNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
PGNY Yearly EPS VS EstimatesPGNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2 2.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 38.37, PGNY can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of PGNY is on the same level as its industry peers.
When comparing the Price/Earnings ratio of PGNY to the average of the S&P500 Index (27.08), we can say PGNY is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 22.36, the valuation of PGNY can be described as rather expensive.
PGNY's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of PGNY to the average of the S&P500 Index (22.67), we can say PGNY is valued inline with the index average.
Industry RankSector Rank
PE 38.37
Fwd PE 22.36
PGNY Price Earnings VS Forward Price EarningsPGNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PGNY is on the same level as its industry peers.
PGNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PGNY is cheaper than 86.14% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.23
EV/EBITDA 18.71
PGNY Per share dataPGNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of PGNY may justify a higher PE ratio.
A more expensive valuation may be justified as PGNY's earnings are expected to grow with 29.43% in the coming years.
PEG (NY)4.87
PEG (5Y)N/A
EPS Next 2Y33.27%
EPS Next 3Y29.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PGNY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROGYNY INC

NASDAQ:PGNY (8/26/2025, 8:00:01 PM)

After market: 22.9 +0.26 (+1.15%)

22.64

-0.5 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners100.04%
Inst Owner Change1.77%
Ins Owners1.36%
Ins Owner Change1.55%
Market Cap1.95B
Analysts80
Price Target29.29 (29.37%)
Short Float %9.8%
Short Ratio7.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.43%
Min EPS beat(2)-11.77%
Max EPS beat(2)14.63%
EPS beat(4)2
Avg EPS beat(4)-0.31%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)9.53%
EPS beat(12)9
Avg EPS beat(12)48.1%
EPS beat(16)13
Avg EPS beat(16)104.01%
Revenue beat(2)2
Avg Revenue beat(2)2.57%
Min Revenue beat(2)1.96%
Max Revenue beat(2)3.19%
Revenue beat(4)3
Avg Revenue beat(4)1.39%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.46%
Revenue beat(16)8
Avg Revenue beat(16)-0.53%
PT rev (1m)7.49%
PT rev (3m)5.24%
EPS NQ rev (1m)3.78%
EPS NQ rev (3m)-20.84%
EPS NY rev (1m)10.16%
EPS NY rev (3m)3.19%
Revenue NQ rev (1m)2.5%
Revenue NQ rev (3m)1.58%
Revenue NY rev (1m)2.64%
Revenue NY rev (3m)2.97%
Valuation
Industry RankSector Rank
PE 38.37
Fwd PE 22.36
P/S 1.57
P/FCF 10.23
P/OCF 9.64
P/B 3.78
P/tB 3.99
EV/EBITDA 18.71
EPS(TTM)0.59
EY2.61%
EPS(NY)1.01
Fwd EY4.47%
FCF(TTM)2.21
FCFY9.77%
OCF(TTM)2.35
OCFY10.38%
SpS14.44
BVpS5.99
TBVpS5.68
PEG (NY)4.87
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.98%
ROE 10.31%
ROCE 14.2%
ROIC 10.87%
ROICexc 24.96%
ROICexgc 28.14%
OM 6.18%
PM (TTM) 4.28%
GM 22.34%
FCFM 15.31%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score8
Asset Turnover1.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 293.7%
Cap/Sales 0.95%
Interest Coverage 250
Cash Conversion 250.02%
Profit Quality 358.02%
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z 7.73
F-Score8
WACC8.92%
ROIC/WACC1.22
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y7.88%
EPS Next 2Y33.27%
EPS Next 3Y29.43%
EPS Next 5Y32.47%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%
Revenue Next Year9.66%
Revenue Next 2Y9.74%
Revenue Next 3Y10.28%
Revenue Next 5Y8.86%
EBIT growth 1Y7.81%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year28.01%
EBIT Next 3Y18.46%
EBIT Next 5Y15.38%
FCF growth 1Y14.92%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y19.24%
OCF growth 3Y90.18%
OCF growth 5YN/A